Cargando…
New hypoglycemic agents and the kidney: what do the major trials tell us?
As the burden of diabetic kidney disease continues to expand, new therapies to preserve renal function or prevent diabetic nephropathy are urgently needed. In the past decade, a number of new hypoglycemic classes have emerged, each with a unique profile of action and benefits. Here we review the imp...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
F1000 Research Limited
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259591/ https://www.ncbi.nlm.nih.gov/pubmed/30542615 http://dx.doi.org/10.12688/f1000research.16135.1 |